Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Tasocitinib plus Methotrexate Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494

NCT01741493
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
ABT-494, Placebo, Tofacitinib
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 75 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
5
States / cities
Miami, Florida • Cincinnati, Ohio • Duncansville, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Sep 18, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

NCT00960440
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 18, 2026, 5:43 PM EDT
Recruiting Phase 3 Interventional

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

NCT03414502
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Methotrexate, Abatacept, Adalimumab, Azathioprine, Baricitinib, Certolizumab, Etanercept, Golimumab, Hydroxychloroquine, Infliximab, Leflunomide, Minocycline, Rituximab, Sarilumab, Sulfasalazine, Tofacitinib
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 18, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate

NCT02147587
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tofacitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
36
States / cities
Jonesboro, Arkansas • Los Angeles, California • Santa Maria, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Sep 18, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate

NCT02996500
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PF-06650833, Placebo, Tofacitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
15
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Clearwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Sep 18, 2026, 5:43 PM EDT
Completed Phase 4 Interventional Results available

Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis

NCT02831855
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Methotrexate, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
59
States / cities
Huntsville, Alabama • Gilbert, Arizona • Peoria, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Sep 18, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

NCT00853385
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Placebo, Biologic TNFi
Drug · Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
38
States / cities
Gilbert, Arizona • Glendale, Arizona • Mesa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 18, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

A Study To Evaluate The Mechanism Of Action Of CP-690,550 In Patients With Rheumatoid Arthritis

NCT00976599
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550 + methotrexate, Placebo + Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Frederick, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Sep 18, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis

NCT00413660
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
33
States / cities
Gilbert, Arizona • Hot Springs, Arkansas • Upland, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2013 · Synced Sep 18, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

Comparing The Effectiveness And Safety Of 2 Doses Of An Experimental Drug, CP-690,550, To Methotrexate (MTX) In Patients With Rheumatoid Arthritis Who Have Not Previously Received MTX

NCT01039688
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Disease-modifying antirheumatic drug
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
956 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
41
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 18, 2026, 5:43 PM EDT
Completed Phase 4 Interventional

Determination of the Optimal Treatment Target in Ulcerative Colitis

NCT04259138
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C
Biological
Lead sponsor
Alimentiv Inc.
Other
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
5
States / cities
Ypsilanti, Michigan • New York, New York • Asheville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 18, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)

NCT01164579
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tasocitinib plus Methotrexate, Tofacitinib plus placebo methotrexate, Placebo tofacitinib plus Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Gilbert, Arizona • Huntington Beach, California • Upland, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Sep 18, 2026, 5:43 PM EDT
Completed Phase 4 Interventional Results available

An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate

NCT02187055
View directory record Official record
Conditions
Rhematoid Arthritis
Interventions
Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
60
States / cities
Huntsville, Alabama • Gilbert, Arizona • Covina, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2018 · Synced Sep 18, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate

NCT00847613
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
37
States / cities
Huntsville, Alabama • Tucson, Arizona • San Diego, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 18, 2026, 5:43 PM EDT
Recruiting Phase 2 Interventional

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

NCT07138898
View directory record Official record
Conditions
Rheumatic Disease
Interventions
Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
Drug · Biological
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 18, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Results available

Co-Administration Of Methotrexate And CP-690,550

NCT01745055
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550 (tofacitinib), Methotrexate (MTX)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
4
States / cities
Daytona Beach, Florida • Fort Lauderdale, Florida • Miramar, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2013 · Synced Sep 18, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

A Study To Assess the Immune Response Following Administration Of Influenza and Pneumococcal Vaccines To Subjects With Rheumatoid Arthritis Receiving CP-690,550 Or Placebo

NCT01359150
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
51
States / cities
Gilbert, Arizona • Paradise Valley, Arizona • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Sep 18, 2026, 5:43 PM EDT